Non-Small-Cell Lung Cancer
Conditions
Interventions
nab-paclitaxel 100mg/m2 Day1,8,15 Every four weeks
Sponsors
Kansai Medical University Hirakata Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically proven stage IIIB/IV non-small cell lung cancer 2) Pretreated with one regimen. 3) ECOG PS : 0-2 4) chemo naïve 5) Adequate organ function 6) Age: 20- years old 7) At least one measurable lesion by RECIST 8)without other active double cancer. 9) Life expectancy more than three months 10) Written informed consent
Exclusion criteria
Exclusion criteria: 1)With severe myelosupression. 2) With active infectious disease 3) Interstitial pneumonia or pulmonary fibrosis detectable on X ray 4)History of cardiac dysfunction 5)History of treatment with paclitaxel. 6)History of albumin sensitivity 7)Symptomatic brain metastasis 8)Pericardial or pleural effusion requiring drainage 9) History of serious disease condition 10) History of drug allergy 11) With pregnancy or lactation 12) Without measurable lesion by RECIST 13) With grade2 or more neuropathy 14) Evaluated to be ineligible by a physician for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response Rate progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival, Overall Survival, Safety | — |
Countries
Japan
Contacts
Public ContactTakashi Yokoi
Kansai Medical University Hirakata Hospital Thoracic oncology
Outcome results
None listed